CanSinoBIO developed a highly effective COVID vaccine with an inhalant version
pharmaphorum
JULY 18, 2022
Considering we already use this adenovirus-based viral vector vaccine technology for the Ebola vaccine, we expect to get to two years of shelf life,” Morgon states. The whole package should be available, the Chinese package, for countries’ regulatory authorities to license the product in the last quarter of this year,” Morgon states.
138 
Let's personalize your content